Will SAFE Banking Pass or Not?

Welcome to our latest Trade to Black podcast. It’s been a productive week in psychedelics, but we’re back to looking at the latest news in cannabis. This episode, host Shadd Dales, lead financial writer Benjamin A. Smith, and millennial entrepreneur Anthony Varrell are talking about Chuck Schumer pushing for the approval of SAFE Banking.

Charles Ellis Schumer has held a seat as one of the senators of the New York since 1999. As a Democrat and a public supporter of cannabis reform, Chuck Schumer’s being in favor of the SAFE Banking Act is not an unusual move. But should we trust his actions for the industry?

Schumer previously introduced the Cannabis Administration and Opportunity Act twice without movement. With SAFE Banking having been originally introduced over a decade ago and stalling out in senate again only just recently, Washington’s general feelings on cannabis appears to be rather clear.

Where does this leave the SAFE Banking Act now? Is it likely that Schumer might have any success this push through? Or must we rely on HHS Secretary Becerra rescheduling the drug itself? If SAFE passes, what comes next after the politicians vote yes?

We also talk about Ron DeSantis’ campaigns and candidacy for president. How is he comparing to Trump’s campaigns, and how this will impact the market? Will a DeSantis presidency make or break the cannabis industry?

We’ll briefly recap the past week and MAPS’ incredible Psychedelic Science Conference which was attended by 12,000+ experts and practitioners in the healthcare sector. It might just be a real turning point in education and interest, and it’s undoubtable that it will wield some major influence in the psychedelics industry.  Did the conference have enough impact to push that rising momentum into a ground swell, allowing it to become the turning point for investors and overall healthcare landscape?

We’ve got some thoughts.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More